The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. (February 2015)

• Record Type: Journal Article
• Authors: Saveanu, Radu; Etkin, Amit; Duchemin, Anne-Marie; Goldstein-Piekarski, Andrea; Gyurak, Anett; Debattista, Charles; Schatzberg, Alan F.; Sood, Satish; Day, Claire V.A.; Palmer, Donna M.; Rekshan, William R.; Gordon, Evian; Rush, A. John; Williams, Leanne M.
• Is Part Of: Journal of psychiatric research. Volume 61(2015:Feb.)
• Page Start: 1
• Page End: 12
• Publication Date: 2015-02
• Subjects: Major depressive disorder -- International practical trial -- Escitalopram -- Sertraline -- Venlafaxine-XR -- Response and remission; Psychiatry -- Periodicals; Mental Disorders -- Periodicals; Maladies mentales -- Périodiques; Psychiatry; Electronic journals; Periodicals; 616.89005
• DOI: 10.1016/j.jpsychires.2014.12.018
• Languages: English
• ISSNs: 0022-3956

Abstract

Abstract: We aimed to characterize a large international cohort of outpatients with MDD within a practical trial design, in order to identify clinically useful predictors of outcomes with three common antidepressant medications in acute-phase treatment of major depressive disorder (MDD). The international Study to Predict Optimized Treatment in Depression has presently enrolled 1008 treatment-seeking outpatients (18–65 years old) at 17 sites (five countries). At pre-treatment, we characterized participants by symptoms, clinical history, functional status and comorbidity. Participants were randomized to receive escitalopram, sertraline or venlafaxine-extended release and managed by their physician following usual treatment practices. Symptoms, function, quality of life, and side-effect outcomes were assessed 8 weeks later. The relationship of anxiety to response and remission was assessed by comorbid Axis I diagnosis, presence/absence of anxiety symptoms, and dimensionally by anxiety symptom severity. The sample had moderate-to-severe symptoms, but substantial comorbidity and functional impairment. Of completers at week 8, 62.2% responded and 45.4% reached remission on the 17-item Hamilton Rating Scale for Depression; 53.3% and 37.6%, respectively on the 16-item Quick Inventory of Depressive Symptoms. Functional improvements were seen across all domains. Most participants had side effects that occurred with a frequency of 25% or less and were reported as being in the "none" to minimal/mild range for intensity and burden. Outcomes did not differ across medication groups. More severe anxiety symptoms at pre-treatment were associated with lower remission rates across all medications, independent of depressive severity, diagnostic comorbidity or side effects. Across medications, we found consistent and similar improvements in symptoms and function, and a dimensional prognostic effect of comorbid anxiety symptoms. These equivalent outcomes across treatments lay the foundation for identifying potential neurobiological and genetic predictors of treatment outcome in this sample. Highlights: We undertook a practical biomarker trial of 1008 outpatients with depression. Treatment (randomly) was escitalopram, sertraline or venlafaxine-XR for 8 weeks. Clinician-rated response/remission rates were 62.2%/45.4%; self-report, 53.3%/37.6%. Quality of life, social functions and emotion regulation improved post-treatment. More severe symptoms of anxious arousal contributed to poorer remission outcomes.